Encorafenib/Binimetinib for the Treatment of BRAF-mutant Advanced, Unresectable, or Metastatic Melanoma: Design, Development, and Potential Place in Therapy
OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s171693
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2018
Authors
Publisher
Informa UK Limited